| Date | Title | Description | |
|---|---|---|---|
| 08 Jul 2024 | Other relevant information | The Company informs about the dividends payment. | Download |
| 04 Jul 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2024 | Download |
| 24 Jun 2024 | Announcement of General Shareholders' Meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
| 11 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program | Download |
| 07 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 31 May and 6 June 2024 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |